Vanguard Group Inc's Ownership in Nektar Therapeutics

The Vanguard Group Inc filed a Schedule 13G/A amendment with the SEC, reporting its ownership of 948,647 shares of Nektar Therapeutics' common stock, representing 4.98% of the total shares outstanding. The filing indicates that Vanguard has sole dispositive power over 833,793 shares and shared dispositive power over 114,854 shares. The shares are held in the ordinary course of business and not for the purpose of influencing the control of Nektar Therapeutics. The filing also notes that no single client of Vanguard owns more than 5% of the shares. The amendment was signed by Ashley Grim, Head of Global Fund Administration, on October 31, 2025.